Management of patients with chronic renal insufficiency in the Northeastern United States.

Comorbid conditions that develop during chronic renal insufficiency (CRI) contribute to the high morbidity and mortality among patients with end-stage renal disease (ESRD). Thus, appropriate management during CRI may lead to improved ESRD outcomes. A retrospective cohort study was performed to describe the management of patients with CRI. A total of 602 patients with CRI (creatinine > or =1.5 mg/dl for women and > or =2.0 mg/dl for men) were seen between October 1994 and September 1998 at five nephrology outpatient clinics in the Boston area. The mean (SD) age of the patients was 63 (15.5) yr, and 53% were male. At the first nephrology visit, mean (SD) serum creatinine was 3.2 (1.6) mg/dl, and mean (SD) predicted GFR was 22.3 (8.9) ml/min per 1.73 m(2). Laboratory tests for iron levels were performed in only 18% of patients, serum parathyroid hormone levels were obtained in only 15%, lipid studies were obtained in fewer than half, and among patients with diabetes, only 28% had a glycosylated hemoglobin level measured. A hematocrit <30% was present in 38%, and abnormal calcium-phosphorus metabolism was noted in 55%. Only 59% of patients who had hematocrit <30% received recombinant human erythropoietin. Among patients who received recombinant human erythropoietin, only 47% received iron. Angiotensin-converting enzyme inhibitor use was recorded for only 65% of patients with diabetes (49% of patients overall). Among patients who were known to have progressed to ESRD, only 41% had permanent access placed before initiation of dialysis. There seems to be room for improvement in the management of patients with CRI, which could result in a slower rate of progression of CRI and reduced severity of comorbid conditions.

[1]  B. Pereira,et al.  Optimization of pre-ESRD care: the key to improved dialysis outcomes. , 2000, Kidney international.

[2]  M. Drezner,et al.  Altered divalent ion metabolism in early renal failure: role of 1,25(OH)2D. , 1985, Kidney international.

[3]  A. Kausz,et al.  Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. , 1999, Journal of the American Society of Nephrology : JASN.

[4]  R. Chesney,et al.  Morbidity and Mortality of Renal Dialysis: An NIH Consensus Conference Statement , 1994, Annals of Internal Medicine.

[5]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[6]  J. Bergström Nutrition and mortality in hemodialysis. , 1995, Journal of the American Society of Nephrology : JASN.

[7]  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.

[8]  A. Levey,et al.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.

[9]  B. Pereira,et al.  Hematocrit Level Associated Mortality in Hemodialysis Patients, by Ma JZ, Ebben J, Xia H, Collins AJ. J Am Soc Nephrol 10:610–619, 1999 , 2000, Seminars in dialysis.

[10]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[11]  F. Port,et al.  Morbidity and mortality in dialysis patients. , 1994, Kidney international.

[12]  S. Greenfield,et al.  Recent developments and future issues in the use of health status assessment measures in clinical settings. , 1992, Medical care.

[13]  R. Saracho,et al.  The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[14]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[15]  J. Singer,et al.  Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. Assal,et al.  [Long-term complications in diabetes mellitus]. , 1989, Acta medica portuguesa.

[17]  A. Collins,et al.  Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[18]  David C. Murray,et al.  The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  C. Schmid,et al.  Comorbidity Assessment in Hemodialysis and Peritoneal Dialysis Using the Index of Coexistent Disease , 2000, Seminars in dialysis.

[20]  P. Ratcliffe,et al.  Late referral for maintenance dialysis. , 1984, British medical journal.

[21]  G. Beck,et al.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. , 1997, Kidney international.

[22]  J. Sondheimer,et al.  An analysis of the adequacy of preparation for end-stage renal disease care in Michigan. Michigan Renal Plan Task Force. , 1995, ASAIO journal.

[23]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[24]  W. Keane,et al.  Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  T. Shoji,et al.  Atherosclerosis in uremia: possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation. , 1997, Kidney international. Supplement.

[26]  S. Schwab,et al.  Assessing the adequacy of vascular access and its relationship to patient outcome. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  M. Rocco,et al.  The costs of hospitalizations due to hemodialysis access management. , 1995, Nephrology news & issues.

[28]  S. Klahr The modification of diet in renal disease study. , 1989, The New England journal of medicine.

[29]  R. Rettig The social contract and the treatment of permanent kidney failure. , 1996, JAMA.

[30]  J. McGill,et al.  The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. , 1995, The American journal of medicine.

[31]  A. Levin,et al.  Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[33]  B. Kasiske,et al.  Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  A. Kausz,et al.  Hospital utilization among chronic dialysis patients. , 2000, Journal of the American Society of Nephrology : JASN.

[35]  E. Ritz,et al.  A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. , 1994, Journal of the American Society of Nephrology : JASN.

[36]  J. Adamson,et al.  The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. , 1990, Contributions to nephrology.

[37]  H. Lebovitz,et al.  Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. , 1994, Kidney international. Supplement.

[38]  A. Collins,et al.  Hematocrit levels and hospitalization risks in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.

[39]  A. Kausz,et al.  Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. , 1999, Journal of the American Society of Nephrology : JASN.

[40]  E G Lowrie,et al.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[42]  J. Coresh,et al.  Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  R. Parker,et al.  Spontaneous dietary protein intake during progression of chronic renal failure. , 1995, Journal of the American Society of Nephrology : JASN.

[44]  W. McClellan,et al.  Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  D. McKusick,et al.  The next ten years of health spending: what does the future hold? The Health Expenditures Projection Team. , 1998, Health affairs.